Myelodysplastic syndromes

From Libre Pathology
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Myelodysplastic syndromes, abbreviated MDS, can be thought of a pre-leukemia/pre-lymphoma.

They should not be confused with myeloproliferative neoplasms.

Overview

Lab findings

  • +/-Anemia.
  • +/-Neutropenia.
  • +/-Thrombocytopenia.

Notes:

  • MDS is usu. an incidental finding, i.e. it is asymptomatic.

Associations

Syndromes associated with MDS:[1]

  • Fanconi syndrome.
  • Diamond-blackfan syndrome.
  • Shwachman-diamond syndrome.

Diagnostic criteria

All of the following:[1]

  1. At least 6 months + persistent.
  2. Dysplasia.
    • Cytologic:
      • Need >=10% abnormal.
    • Cytogenetic.
  3. All other causes excluded.
  4. Blast percentage <20%.
    • If >=20% = leukemia.
    • Criteria blast percentage:
      • Bone marrow: 500 nucleated cells - includes erythroblasts, plasma cells; excludes megakaryocytes.
      • Peripheral blood: 200 leukocytes.

Required clinical information

  • CBC - usu. macrocytic anemia.
  • Rx - may be Rx effect.
  • Peripheral blood film.
  • Clinical history (symptoms/presentation/PMHx).

Laboratory work-up

  • H&E stain.
  • Giemsa/Wright stain.
  • Iron stain.
  • Gomori silver stain.

DDx of MDS

  1. Nutritional deficiency.
    • Vitamin B12.
    • Folate.
  2. Toxic exposures.
    • Rx.
      • G-CSF.
    • Biologic agents.
    • Heavy metals.
    • Chemotherapy.
  3. Infections.
    • Parovirus B19.
  4. Other.
    • Paroxysmal nocturnal hemoglobinuria (PNH).[2] (???)
    • Congenital hematopoietic disorder.
      • Congenital dyserythropoietic anemia.

Bone marrow specimens

Normal

  • Age (years) ~ percentage of fat.
    • Example 80 years old has ~ 80% fat in marrow space.

Erythroblasts:

  • Typically away from bone.

Megakaryocytes:

  1. Alone - not in clusters.
  2. Not close to bone.

Myeloid cells:

  • Adjacent to bone.

Histologic features

  • Auer rods - used to be diagnostic of MDS regardless of blast count.

Dyserythropoiesis

  • Abnormal RBC formation.

Histology

Nuclear

Features:[1]

  • Nuclear budding.
  • Intranuclear bridging (nuclei fail to separate post-division).
  • Multinucleation.
  • Megablastoid change.
    • May be hard to see.
  • Karyorrhexis (nuclear fragmentation).

Cytoplasmic

Features:[1]

  • Ring sideroblasts.
    • Rim of RBC has ring of iron.
  • Vacuolization.

Dysgranulopoiesis

  • Abnormal granulocyte formation.

Histology

Features:[1]

  • Nuclear hypolobation (pseudo Pelger-Huët).
  • Hypersegmentation.
    • May be seen in vitamin B12 deficiency, Rx.
  • Cytoplasmic hypogranulation.
  • Pseudo-Chediak-Higashi granules.
  • Small size.

Dysmegakaryocytopoiesis

  • Abnormal megakaryocyte formation.

Histology

Features:[1]

  • Micromegakaryoctes with hypolobated nuclei.
  • Non-lobated nuclei of any size.
  • Multiple widely separated nuclear lobes.

Image:

IHC

Typical IHC in work-up of MDS:

  • CD34 - (myeloid) progenitor/precursor cells.
  • CD117 - (myeloid) progenitor/precursor cells, mast cells.
  • Tryptase - mast cells, immature basophils.
    • Uncommonly done.
  • CD61 - megakaryocytes.
  • CD42b - megakaryocytes.
  • CD20 - B cells.
  • CD3 - T cells.
  • Glycophorin A - erythroid cells.
  • Glycophorin C - erythroid cells.

Notes:

  • Other markers:
    • Factor VIII.
    • vWF.
  • Blasts - the gold standard: histomorphology.
    • Most blasts are CD34 +ve.
      • Flow cytometry not useful (yet) for MDS -- as CD34 +ve != blast; may change with more multiplexing.
    • CD117 marks some blasts that are CD34 -ve.

Cytogenetics

  • Important in the Dx and prognostication of MDS; however, only ~50% have a cytogenetic abnormality based on karyotyping.

Common changes:

  1. Isolated del(5q).
  2. Isolated del(17p).
    • Assoc. with pseudo-Pelger-Huet. (???)
  3. Monosomy 7.
  4. Monosomy 8.

There is a scoring system for cytogenetic abnormalities International Prognostic Scoring System,[3] abbreviated IPSS:

  • Higher score = worse outcome.

WHO classification (2008)

  • Refractory cytopenia with unilineage dysplasia (RCUD).
    1. Anemia.
    2. Neutropenia
    3. Thrombocytopenia.
  • Refractory anemia with ringed sideroblasts (RARS).
  • Refractory cytopenia with multilineage dysplasia (RCMD).[4]
  • Refractory anemia with excess blasts (RAEB).
    • RAEB-1.
    • RAEB-2: Auer rods or >= 10% blasts.
  • MDS with isolated del(5q).
  • MDS unclassifiable.

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 D. Good. 21 March 2011.
  2. URL: http://emedicine.medscape.com/article/207468-overview. Accessed on: 29 May 2011.
  3. Garcia-Manero, G. (Jun 2011). "Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.". Am J Hematol 86 (6): 490-8. doi:10.1002/ajh.22047. PMID 21594886.
  4. Rosati, S.; Mick, R.; Xu, F.; Stonys, E.; Le Beau, MM.; Larson, R.; Vardiman, JW. (Jan 1996). "Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.". Leukemia 10 (1): 20-6. PMID 8558932.